Linden Thomas Advisory Services LLC Boosts Stake in Regeneron Pharmaceuticals, Inc. $REGN

Key Points

• Linden Thomas Advisory Services LLC has increased its stake in Regeneron Pharmaceuticals by 32.8%, now owning 4,235 shares valued at approximately $2.2 million.
• Several other institutional investors, like B & T Capital Management and AG2R LA Mondiale Gestion, have also raised their positions significantly in Regeneron during the second quarter.
• Analysts have varying target price projections for Regeneron, with an average target of $802.35 and a consensus rating of "Moderate Buy."

Linden Thomas Advisory Services LLC grew its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 32.8% during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 4,235 shares of the biopharmaceutical company's stock after buying an additional 1,045 shares during the quarter. Linden Thomas Advisory Services LLC's holdings in Regeneron Pharmaceuticals were worth $2,223,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently made changes to their positions in the stock. B & T Capital Management DBA Alpha Capital Management raised its position in shares of Regeneron Pharmaceuticals by 56.0% during the 2nd quarter. B & T Capital Management DBA Alpha Capital Management now owns 5,476 shares of the biopharmaceutical company's stock valued at $2,875,000 after buying an additional 1,966 shares in the last quarter. AG2R LA Mondiale Gestion D Actifs raised its position in shares of Regeneron Pharmaceuticals by 8.5% during the 2nd quarter. AG2R LA Mondiale Gestion D Actifs now owns 4,453 shares of the biopharmaceutical company's stock valued at $2,338,000 after buying an additional 348 shares in the last quarter. PKO Investment Management Joint Stock Co raised its position in shares of Regeneron Pharmaceuticals by 22.9% during the 2nd quarter. PKO Investment Management Joint Stock Co now owns 18,800 shares of the biopharmaceutical company's stock valued at $9,870,000 after buying an additional 3,500 shares in the last quarter. Washington Trust Advisors Inc. raised its position in shares of Regeneron Pharmaceuticals by 1.5% during the 2nd quarter. Washington Trust Advisors Inc. now owns 29,961 shares of the biopharmaceutical company's stock valued at $15,730,000 after buying an additional 435 shares in the last quarter. Finally, DDD Partners LLC purchased a new stake in shares of Regeneron Pharmaceuticals during the 2nd quarter valued at $10,760,000. Hedge funds and other institutional investors own 83.31% of the company's stock.

Wall Street Analyst Weigh In

REGN has been the topic of several research reports. Sanford C. Bernstein raised their price objective on shares of Regeneron Pharmaceuticals from $753.00 to $781.00 and gave the company an "outperform" rating in a research report on Wednesday, August 27th. Citigroup increased their target price on shares of Regeneron Pharmaceuticals from $650.00 to $660.00 and gave the company a "buy" rating in a report on Monday, October 13th. BMO Capital Markets increased their target price on shares of Regeneron Pharmaceuticals from $600.00 to $640.00 and gave the company an "outperform" rating in a report on Monday, August 4th. Rothschild & Co Redburn assumed coverage on shares of Regeneron Pharmaceuticals in a report on Thursday, August 14th. They set a "buy" rating and a $890.00 target price on the stock. Finally, Jefferies Financial Group increased their target price on shares of Regeneron Pharmaceuticals from $813.00 to $831.00 and gave the company a "buy" rating in a report on Wednesday, August 27th. Three equities research analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating, seven have assigned a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average target price of $802.35.

Regeneron Pharmaceuticals Price Performance

Shares of Regeneron Pharmaceuticals stock opened at $577.95 on Friday. The firm has a market cap of $61.26 billion, a PE ratio of 14.57, a price-to-earnings-growth ratio of 1.80 and a beta of 0.31. Regeneron Pharmaceuticals, Inc. has a 12-month low of $476.49 and a 12-month high of $943.83. The company has a quick ratio of 3.72, a current ratio of 4.60 and a debt-to-equity ratio of 0.09. The company's fifty day simple moving average is $576.32 and its two-hundred day simple moving average is $562.62.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last announced its quarterly earnings results on Friday, August 1st. The biopharmaceutical company reported $12.89 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $8.43 by $4.46. The business had revenue of $3.68 billion for the quarter, compared to analyst estimates of $3.30 billion. Regeneron Pharmaceuticals had a net margin of 31.37% and a return on equity of 15.06%. The company's revenue was up 3.6% on a year-over-year basis. During the same quarter last year, the firm earned $11.56 EPS. As a group, equities analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Wednesday, September 3rd. Shareholders of record on Monday, August 18th were issued a $0.88 dividend. This represents a $3.52 dividend on an annualized basis and a yield of 0.6%. The ex-dividend date of this dividend was Monday, August 18th. Regeneron Pharmaceuticals's dividend payout ratio (DPR) is 8.87%.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.

Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.